Just-Evotec Biologics Wins BARDA Project Agreement Valued At Up To $10M To Optimize Biomanufacturing Of Monoclonal Antibody Cocktail Targeting Ebola And Sudan Virus

Just-Evotec Biologics has secured a project agreement with BARDA valued at up to $10 million to enhance the biomanufacturing of a monoclonal antibody cocktail aimed at combating Ebola and the Sudan virus. The initiative will utilize Just-Evotec's advanced biomanufacturing platform to achieve higher yields and cost-efficient production, thereby bolstering U.S. government capabilities in responding to hemorrhagic fever outbreaks.